Funding

NeuroXess announced a RMB 700 million Series B round co-led by Guotou Juli, Shenzhen Capital Group, and Qinzhi Capital. The company says proceeds will support multicenter registration trials and regulatory approval work for its fully implantable, fully wireless, fully functional BCI system, manufacturing facilities, next-generation products, and BCI–AI integration. It reports that the registration trial has started at Huashan Hospital, Fudan University, and that its planned factory covers 14,300 square meters, targeting production capacity on the scale of 10,000 systems. These clinical and manufacturing updates are company disclosures: starting a registration trial does not mean device approval, and planned capacity is not current output.

An August 2026 Neurotech Reports analysis cites Neuralink’s June 2025 $650 million Series E when examining uneven funding. Author Sharena Rice argues that large rounds do not imply broadly easier financing for startups, and considers platform funding alongside treatment-network expansion. Her assessment of tighter funding paths is an interpretation; specific award totals for the next NIH Blueprint MedTech cycle were not public.

One year after its June 2025 launch, Neuro Space (脑智天地) — Shanghai's BCI industry cluster at the Hongqiao International Medical Center and China's first dedicated BCI industrial zone — has entered full operation across its 25,000 m² pilot area. As of July 2026, the cluster hosts 52 registered BCI companies and 22 startup incubators spanning flexible electrodes, BCI chips, ultrasound-based interfaces, and vision restoration. On the commercialization front, the world's first approved invasive BCI medical device, developed in Shanghai, received regulatory clearance in 2026, with its first clinical prescription issued in July. Five additional Class III devices are currently in clinical trials or under regulatory review. Shanghai accounts for nearly 60% of China's BCI financing events, totaling approximately RMB 2.117 billion. Products showcased at a recent open-day event include a non-invasive brain-controlled consumer device driven by EEG-based attention metrics, an integrated transcranial magnetic stimulation navigation system for depression treatment, and LingXi Cloud, a clinical data platform housing over 2.1 million cases of multimodal brain-disorder data at petabyte scale.